Cancer Monoclonal Antibodies Market Forecast to 2017

News provided by

Aug 13, 2013, 04:50 ET

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Monoclonal Antibodies Market Forecast to 2017
http://www.reportlinker.com/p01595379/Cancer-Monoclonal-Antibodies-Market-Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies.

Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. According to RNCOS' report, "Cancer Monoclonal Antibodies Market Forecast to 2017", the market for cancer mAbs is estimated at US$ 23 Billion, and is expected to grow to US$ 33 Billion by 2017.

The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs.

In our report, we have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of the top five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs.

Through our pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to breast cancer, solid tumors and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs.

Finally, RNCOS concludes its report with a competitive analysis of the major mAb players, providing brief descriptions of every player along with a list of current and pipeline mAbs. The report can therefore, provide assistance in evaluating the current market, discovering potential areas and analyzing the competitive environment.

1. Analyst View

2. Research Methodology

3. The Global Burden of Cancer

3.1 Cancer - A Leading Cause of Death
3.2 Current and Future Cancer Cases: By Type and Geography
3.3 Common Causes of Cancer

4. Global Cancer Market Outlook to 2017

4.1 Current and Future Growth
4.2 Analysis by Therapeutic Sub-Segments

5. Monoclonal Antibodies: Introduction and Working

5.1 Types of mAbs
5.1.1 Murine Antibodies
5.1.2 Chimeric and Humanized Antibodies
5.1.3 Fully Human Antibodies
5.2 Conjugated Cancer Therapies using mAbs
5.2.1 Radioimmunotherapy
5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
5.2.3 Immunoliposomes
5.2.4 Immunotoxin
5.2.5 Immunocytokine
5.3 Cancer Monoclonal Antibody Therapies
5.3.1 Avastin (Bevacizumab)
5.3.2 Rituxan (Rituximab)
5.3.3 Herceptin (Trastuzumab)
5.3.4 Erbitux (Cetuximab)
5.3.5 Vectibix (Panitumumab)
5.3.6 Zevalin (Ibritumomab)
5.3.7 Bexxar (Tositumomab)
5.3.8 Arzerra (Ofatumumab)
5.3.9 Yervoy (Ipilimumab)
5.3.10 Adcetris (Brentuximab Vedotin)
5.3.11 Perjeta (Pertuzumab)
5.3.12 Kadcyla (Ado-trastuzumab Emtansine)

6. Industry Trends and Drivers

6.1 Strategic Activities or Alliances on Rise
6.2 New Clinical Approvals Showing Promising Future
6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
6.4 Antibody Drug Conjugates for Cancer Therapy

7. Global Cancer mAbs Market Outlook to 2017

7.1 Market Size
7.2 Cancer mAbs: Approval History and Market Share
7.3 Cancer mAbs: Current and Future Market Size
7.3.1 Avastin (Bevacizumab)
7.3.2 MabThera/Rituxan (Rituximab)
7.3.3 Herceptin (Trastuzumab)
7.3.4 Erbitux (Cetuximab)
7.3.5 Vectibix (Panitumumab)
7.4 Country-Level Analysis
7.4.1 US
7.4.2 Japan
7.4.3 Europe
7.5 Market Share of Key Players

8. Pipeline Analysis of Cancer Monoclonal Antibodies

9. Competitive Landscape

9.1 Roche
9.2 Eli Lilly
9.3 GlaxoSmithKline
9.4 Amgen
9.5 Bristol-Myers Squibb
9.6 Seattle Genetics
9.7 Spectrum Pharmaceuticals
9.8 Genmab

List of Figures:

Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008
Figure 3-2: Global - Number of Cancer Deaths (Million), 2008 & 2030
Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 3-4: Global - New Cancer Cases by Region (%), 2009
Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020
Figure 4-1: Global - Pharmaceuticals Market by Therapy Areas (%), 2012 & 2017
Figure 4-2: Global - Cancer Drugs Market (Billion US$), 2012-2017
Figure 4-3: Global - Cancer Drugs Market by Player (%), 2012
Figure 4-4: Global - Cancer Drugs Market by Therapeutic Segment (%), 2012
Figure 5-1: Types of Monoclonal Antibodies
Figure 5-2: Hybridoma Technology for Mouse-derived Monoclonal Antibodies
Figure 7-1: Global - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-2: Global - Cancer mAbs Market by Product (%), 2012
Figure 7-3: Global - Avastin Sales (Billion US$), 2012-2017
Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2012-2017
Figure 7-5: Global - Herceptin Sales (Billion US$), 2012-2017
Figure 7-6: Global - Erbitux Sales (Billion US$), 2012-2017
Figure 7-7: Global - Vectibix Sales (Million US$), 2012-2017
Figure 7-8: Global - Cancer mAbs Market by Country/Region (%), 2012
Figure 7-9: US - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-10: Japan - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-11: Europe - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-12: Global - Cancer mAbs Market by Player (%), 2012
Figure 8-1: Global - Breakup of Cancer mAbs in Pipeline by Phase

List of Tables:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)
Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)
Table 7-1: Global - List of FDA Approved Cancer mAbs with Year of Approval and Indication
Table 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2013)
Table 7-3: US - List of Approved Cancer mAbs with Year of Approval
Table 7-4: US - Cancer mAbs Expenditure in Clinics (Million US$), 2011 & 2012
Table 7-5: Japan - Number of Cancer Deaths by Type and Gender (2010 & 2011)
Table 7-6: Japan - List of Approved Cancer mAbs with Year of Approval
Table 7-7: EU - Number of Cancer Cases and Deaths by Type (2012)
Table 7-8: EU - List of Approved Cancer mAbs with Year of Approval
Table 8-1: Global - Pipeline Analysis of Cancer mAbs
Table 8-2: Global - Number of Cancer mAbs in Pipeline by Type of Cancer
Table 9-1: Roche - Key Cancer Monoclonal Antibodies in Market
Table 9-2: Roche - Key Monoclonal Antibodies in Pipeline
Table 9-3: Eli Lilly - Key Cancer Monoclonal Antibodies in Market
Table 9-4: Eli Lilly - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-5: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Market
Table 9-6: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-7: Amgen - Key Cancer Monoclonal Antibodies in Market
Table 9-8: Amgen - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-9: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Market
Table 9-10: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-11: Seattle Genetics - Key Cancer Monoclonal Antibodies in Market
Table 9-12: Seattle Genetics - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-13: Spectrum Pharmaceuticals - Key Cancer Monoclonal Antibodies in Market
Table 9-14: Genmab - Key Cancer Monoclonal Antibodies in Market
Table 9-15: Genmab - Key Cancer Monoclonal Antibodies in Pipeline